Lipophilicity of amphoteric and zwitterionic compounds: a comparative study of determination methods by Ràfols Llach, Clara et al.
1 
 
LIPOPHILICITY OF AMPHOTERIC AND ZWITTERIONIC COMPOUNDS: A 
COMPARATIVE STUDY OF DETERMINATION METHODS 
Clara Ràfols*, Xavier Subirats, Javier Rubio, Martí Rosés, Elisabeth Bosch 
Departament de Química Analítica and Institut de Biomedicina (IBUB), Universitat de 
Barcelona, Martí i Franquès 1-11, E-08028 Barcelona, Spain 
*Corresponding author 
 
 
Dr. Clara Ràfols 
Phone: (+34) 934 034 874, Fax: (+34) 934 021 233, E-mail: crafols@ub.edu 
 
Dr. Xavier Subirats 
Phone: (+34) 934 039 119, Fax: (+34) 934 021 233, E-mail: xavier.subirats@ub.edu 
 
Mr. Javier Rubio 
Present address:  Massó Analítica, S.A. 
   Montsià 4, 08820 El Prat de Llobregat, Spain 
   Phone: (+34) 932 859 797, Fax: (+34) 932 198 165 
   E-mail: jr@masso.com  
 
Prof. Martí Rosés 
Phone: (+34) 934 039 275, Fax: (+34) 934 021 233, E-mail: marti.roses@ub.edu 
 
Prof. Elisabeth Bosch 
Phone: (+34) 934 021 284, Fax: (+34) 934 021 233, E-mail: e.bosch@ub.edu 
  
2 
 
Abstract 
Common drugs intended for action in plasma (antibacterials, antiallergics, diuretics…) often 
display both acidic and basic behavior, and some of these amphoteric compounds can appear 
as zwitterions. In such cases, accurate profiling of lipophilicity vs. pH, which plays a 
fundamental role in drug pharmacokinetics, might be complex. In the present work two 
common lipophilicity estimation methods based on the drug distribution between 1-octanol 
and aqueous buffer i.e. phase equilibration (shake-flask) and two-phase titration 
(potentiometry), were compared with a high-throughput lipophilicity index, the 
Chromatographic Hydrophobicity Index (CHI). The results were also compared with log Do/w 
pH-profiles calculated by different algorithms from ACD/Labs. Accurate and similar results 
were obtained for both octanol-water approaches but, due to the lower determination times 
and the absence of different ion-pairing buffers, potentiometry was shown to be the most 
convenient method. CHI vs. pH profiles provide rapid and efficient information, which is very 
convenient for lipophilicity screening purposes, but may differ slightly from shake-flask and 
potentiometric results. 
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1. Introduction 
Most compounds of pharmaceutical interest are weak acids or bases. In such cases, changes in 
the pH of the medium (for instance along the gastrointestinal tract) influence the ionization 
state of the molecule and consequently its solubility in aqueous solution and its partition in 
lipidic media. Water-soluble drugs are needed in the case of oral administration and when 
they have to be transported through body fluids, and it is well known that ionization favors 
solubility. Once in solution, the drug’s lipophilicity needs to be increased in order to cross 
lipidic membranes to reach the drug target and thus the presence of the neutral form, which is 
more lipophilic, is preferable. Thus, many drug molecules contain acid-base groups that help 
to change their degree of ionization during the uptake process. Molecules containing 
carboxylic or phenolic groups can be easily identified as weak acids, or in the case of aliphatic 
or aromatic amines, as bases. However, nitrogen atoms can lack acid-base properties (e.g., 
amides), or even exhibit weakly acidic behavior due to delocalization onto adjacent carbonyl 
groups and resonance stabilization (e.g. barbiturates) or due to the electron-withdrawing effect 
of sulfo groups (e.g. sulfonamides) [1]. Very often a drug presents amphiprotic 
characteristics, having both acidic and basic functional groups. The difference between the 
two pKa values has a remarkable impact on the achievable maximum mole fraction of the 
neutral species. For instance, as shown in Fig. 1, an amphiprotic molecule in which the acidic 
and basic groups are only separated by 1 pKa unit can lead at a maximum mole fraction of 
neutral species of about 60%. This fraction is increased to 83% with a pKa distance of 2 units, 
but will only reach a value close to unity beyond a separation of 5 pKa units. This might be an 
issue when measuring the lipophilicity of neutral species of an amphoteric molecule. In the 
particular case of an acidic group that is stronger than a basic one (i.e., acidic pKa < basic pKa) 
zwitterionic species appear, these being electrically neutral but bearing both a negative and a 
positive charge.  
Prediction software can be very useful and convenient for a preliminary and rapid 
estimate of the lipophilicity of potential drug candidates. In general terms and for the most 
commonly used programs, the lipophilicity of the whole molecule is calculated from the 
individual contributions of separate atoms and/or structural fragments, and in some cases 
from intramolecular interactions [2, 3]. In combination with calculated pKa values, such 
software provides a rough estimate of lipophilicity profiles (log Do/w vs. pH), which is very 
useful as a starting point in experimental designs of accurate log Po/w determination. 
In the present study the lipophilicity profiles of several amphoteric drugs were 
determined using the classical methods based on potentiometry [4, 5] and shake-flask [6, 7] 
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over a wide range of pH values, and the results were compared with those derived from 
determination methods based on the fast gradient chromatographic hydrophobicity index 
(CHIMeCN) [8, 9], as well as the prediction made by two different approaches using the 
common ACD/Labs software.  
 
 
2. Material and methods 
2.1 Reagents 
Buffers were prepared from glacial acetic acid (Baker, >99%), phosphoric acid (Merck, 
>85%), citric acid (Fluka, >99.5%), sodium (Baker >99.5%) and potassium dihydrogen 
phosphate (Merck, >99.5%), sodium hydrogen phosphate (Merck, >99%), sodium or 
ammonium hydrogen carbonate (Fluka, >99%), sodium carbonate (Panreac, >99.5%), 
ammonia (Merck, 25%), and anhydrous ammonium acetate (Baker, >99.5%). When 
necessary, small volumes of hydrochloric acid (Merck, 25%) or concentrated sodium 
hydroxide solutions (prepared from pellets, Merck, >99%) were used for pH adjustment. 
Water was obtained from a Milli-Q plus system (Millipore, Billerica, USA) with a resistivity 
of 18.2 MΩ cm. The organic modifiers used in HPLC mobile phases were acetonitrile and 
methanol (Panreac, HPLC grade). Potassium bromide (Merck, >99%) was used as a dead time 
marker. Dimethyl sulfoxide (DMSO) (Merck, >99,9%) and n‐octanol (Merck, >97%) were 
also employed. Titrisol potassium hydroxide and hydrochloric acid from Merck were used as 
titrants for potentiometric measurements, and potassium chloride (Sigma, >99%) as an 
electrolyte for ionic strength adjustment. The drugs (Table 1) were purchased from Sigma–
Aldrich, all of high purity grade (≥98%). 
 
2.2 Instrumentation 
pH was measured using a Crison 5014 combined electrode connected to a GLP 22 
potentiometer from Crison (Alella, Spain), and standard aqueous solutions (pH 4.01, 7.00, and 
9.21) were used for calibration. Partitions were equilibrated using a movil-ROD rotation 
shaker from Selecta (Abrera, Spain) in closed test tubes at 25
o
C. 
 pKa and log Po/w potentiometric measurements were carried out in a GLpKa/D-PAS 
automatic titrator (Sirius Analytical Instruments Ltd., Forest Row, UK).  
HPLC measurements were performed on a Shimadzu (Kyoto, Japan) HPLC system 
consisting of two LC-10ADvp pumps, a SIL-20ACHT auto-injector, an SPD-M10AVvp 
diode array detector and a CTO-10ASvp oven at 25
o
C and a SCL-10Avp controller. A 5 μm, 
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50 x 4.6 mm XTerra RP18 (Waters, Milford, EUA) column was employed. Injection volumes 
were between 10 and 50 μL, and flow rates in the range 1.0–1.5 mL min-1. 
UHPLC data were recorded using a Shimadzu Nexera system with two LC-30AD 
pumps, a DGU-20A5 online degasser, a SIL-30AC autosampler, a SPD-M20A diode array 
detector, a CTO-10ASvp oven at 25ºC, and a CBM-20Alite controller. A 1.7 μm, 50 x 2.1 
mm Waters (Milford, MA, USA) Acquity BEH C18, 50 mm x 2.1 mm column was employed, 
at a flow rate of 0.5 mL min
-1
 and injection volume of 0.2 μL.  
 
2.3 Determination of pKa and log Po/w by potentiometry 
For potentiometric pKa determination about 5 mg of sample were dissolved in 15 mL of water 
or methanol/water mixtures containing 0.15 M of KCl, followed by pre-acidification or pre-
basification, and finally titrated with KOH 0.5 M or HCl 0.5 M. When mixed solvents were 
used, extrapolated aqueous pKa values were calculated according to the Yasuda-Shedlovsky 
procedure. For spectrophotometric pKa determinations, a 5 mM solution of the compound was 
prepared in DMSO, and 50 μL of this stock solution were diluted with 250 μL of KH2PO4 
0.015 M/KCl 0.15 M and 10 mL of KCl 0.15 M. A blank reference titration is required [10-
12].  
 For log Po/w determination about 5 mg of sample were dissolved in the appropriate 
volume ratio of n-octanol (saturated with 0.15 M KCl aqueous solution) and 0.15 M KCl 
aqueous solution (saturated with n-octanol), followed by titration with KOH 0.5 M or HCl 0.5 
M [4]. 
All measurements were performed at 25
o
C, under an inert gas atmosphere, and at least 
three titrations were performed for each compound. 
 
2.4 Determination of log Po/w by shake-flask method 
Volumes of octanol-saturated aqueous buffer and water-saturated octanol were selected 
according to the procedure proposed in a former study [13]. Briefly, a 10 mM sample stock 
solution in DMSO was diluted in the corresponding buffer, 1:100 for regular compounds (-1.0 
< log Do/w < 3.5) and 1:40 for hydrophilic substances (log Do/w < -1.0), followed by the 
addition of octanol in a volume ratio depending on the expected lipophilicity of the 
compound, and then the mixture was stirred for 1 hour at 25
o
C. Finally, the analyte 
concentration was measured by HPLC in the aqueous phase before and after equilibration 
with octanol in the case of regular compounds, or in the octanolic phase for hydrophilic 
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compounds. Thus, for a compound of regular lipophilicity log Do/w values were calculated 
according to the following expression: 
st inj(w) w
o/w
w inj(st) o
Regular compounds: log log 1
  
     
  
A v V
D
A v V
 (1) 
where Vw/Vo is the volume ratio between the aqueous and the octanolic phases, vinj(w) and 
vinj(st) are the injection volumes, and Aw and Ast are the chromatographic peak areas; the 
subscript st refers to the standard solution, i.e. the aqueous solution of the analyte of known 
concentration before the addition of octanol, and w stands for the aqueous phase after the 
equilibration step with octanol. In the case of poorly lipophilic compounds: 
st inj(o) o
o/w
o inj(st) w
Hydrophilic compounds: log log
 
    
 
A v V
D
A v V
 (2) 
where vinj(o) is the injection volume of the octanolic phase after equilibration. 
Several aqueous buffers at ionic strength of 0.10 M were prepared in order to cover a 
pH range between 1.90 and 11.00 (1.90 – 3.10, H3PO4/NaH2PO4; 3.75 – 5.75, 
CH3COOH/NaCH3COO; 6.21 – 8.21, NaH2PO4/Na2HPO4; 7.00 – 9.20, TrisHCl/Tris; 9.30 – 
11.00, NaHCO3/Na2CO3.). These aqueous buffer solutions were saturated in octanol before 
use for at least 24 hours. Selected volumes of aqueous buffers and n-octanol are presented in 
Table 2 according to the expected log Do/w value. The chromatographic elution was performed 
isocratically in the range between 20 and 80% of methanol, depending on the analyte, in 
mobile phases buffered with phosphate at pH 7.4.  
 
2.5 Determination of Chromatographic Hydrophobicity Index 
CHI is a high-throughput methodology lipophilicity descriptor [8] originally intended for 
screening purposes, based on the retention of compounds in a reversed-phase column under a 
fast gradient elution. In the present work CHI measurements were carried out via the UHPLC 
method as described elsewhere, using acetonitrile as the organic modifier and aqueous 
solutions of 50 mM ammonium acetate at the desired pH value (3.0, 7.4, and 11.0) [14]. In the 
case of neutral species, CHI values were converted into a log Po/w lipophilicity scale by means 
of the following relations [15]: 
   o/w,CHI MeCNlog = 0.059 +103 / 0.15 0.80 P CHI HDCA-1 TMSA HOMO - LUMO  (3) 
where HDCA-1/TMSA and HOMO-LUMO are CODESSA [16] molecular descriptors 
accounting for hydrogen-bond acidity and polarizability, respectively (Table 3) [17]. 
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3. Results and discussion 
As mentioned in the introduction, the acidic or basic properties of a molecule, and therefore 
its degree of ionization, play a fundamental role in its lipophilic behavior. In fact, ionization 
can easily reduce the lipophilicity of a substance by about 3 or 4 log Po/w units [12]. This is 
just a rule of thumb, since ionic species partition into the oil phase as ion-pairs and the 
lipophilicity also depends on the nature and concentration of the counter-ion. Consequently, 
determining the lipophilicity of polyprotic compounds is very often a challenging enterprise 
in the drug discovery process, especially in the case of ordinary and zwitterionic ampholytes. 
Thus, for drugs with some structural complexity, software packages may calculate a variety of 
lipophilicity values depending on the differences in their algorithms [2]. Even similar 
computational programs offered by the same provider may show significantly different 
lipophilicity values for the same compound [3]. 
 Two different predictive approaches from the ACD/Labs software, Classic and 
GALAS, were used in this work to calculate the log Do/w drug profile over a wide range of pH 
[18]. Since distribution ratios depend on the partition ratios of individual species, log Po/w 
values of neutral and ionized forms are first calculated by the software, and then estimated 
pKa values of the molecule are used to define the distribution of the species within the pH 
range. Classic log Po/w are calculated from the contributions of atoms, structural fragments 
and intramolecular interactions, whereas GALAS log Po/w are based on a training set 
compiled from experimental data. For pKa estimation, the Classic approach involves Hammet-
type equations and electronic substituent constants, whereas the GALAS procedure is based 
on a database of ionization centers and interaction constants of ionized groups to neighboring 
ionization centers.  
As shown in Fig. 2, pKa values obtained by both approaches were very similar 
(inflection points in calculated log Do/w vs. pH curves), but this was not the case for log Po/w 
values. For instance, there was an almost constant log Do/w shift of more than one unit along 
the whole pH range for benazepril and ciprofloxacin, and this distance increased to over 2 log 
Do/w units for telmisartan. On the other hand, the log Po/w of neutral molecules was 
comparable, whereas this was not the case for ionized species such as esomeprazole, 
mebendazole and sulfamethoxazole. In all cases, the extent of the plateau of maximum 
lipophilicity, corresponding to the log Po/w of the neutral species, depended on the difference 
in pKa between the acidic and the basic groups. For esomeprazole, haloperidol, mebendazole, 
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pantoprazole, and sulfamethoxazole, all of them with ΔpKa ≥ 4, the plateau was clearly 
visible, whereas for substances with ΔpKa ≤ 2 it was simply reduced to an apex.  
Thus, computer programs provide an estimation of the lipophilicity profile of acid-
base compounds, but the proper establishment of this profile requires experimental 
determination. There are several measurement methods and the most common (shake-flask, 
potentiometry, chromatography through CHI) were used in this work, with the results 
obtained for a selected group of amphoteric and zwitterionic compounds being compared 
between methods and with computer estimations. 
As shown earlier, the log Do/w profile of a polyprotic compound depends on the pH of 
the medium, the pKa of the successive dissociation steps, and the partition ratios (log Po/w 
values) of individual species between the aqueous and the octanolic phases, usually expressed 
by:  
'
a
1
'
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1
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 (4) 
where HnX
z
 refers to the fully protonated species (neutral form of a weak acid, or cationic 
species of a weak base) since n is the total number of ionizable groups and z is the maximum 
number of positive charges (z = 0 for acids, z ≥ +1 for bases), and 'ap jK  stands for the mixed 
pKa of the subscript species (i.e. the activity of the proton measured by the glass electrode, but 
the concentration of the acid/base species). In Eq. (4) ionic species are considered to partition 
into the octanolic phase as ion-pairs, normally taking any of the buffer ions as a counter-ion. 
At this point two issues should be taken into consideration: 1) the log Po/w values of ion-pairs 
depend on the nature and concentration of the counter-ion [12]; and 2) 
'
ap jK  values obtained 
from fittings to Eq. (4) depend on the thermodynamic pKa and the ionic activity coefficients, 
which in turn are influenced by the ionic strength of the medium. 
The acidity constants from shake-flask measurements fitted to Eq. (4) and those 
determined by potentiometry are presented in Table 4. It must be pointed out that the latter are 
reported on a concentration scale (
''
ap jK , i.e. the acidity constant expressed in terms of 
concentrations, including that of hydrogen ions, instead of activities, and at different ionic 
strengths: 0.10 M for shake-flask and 0.15 M for potentiometry). Both sets of values showed 
generally good consistency (most differences were less than 0.5 pKa units), indicating that, in 
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most cases, side interactions with the buffer components in the pH range considered for the 
shake-flask fittings are not significant. 
 As shown in Table 5, shake-flask and potentiometric methods led to very similar log 
Po/w values in most instances. Consequently, as the acidity constants were similar, the log Do/w 
profiles shown in Fig. 2 matched quite nicely. Slight differences were observed for the 
zwitterionic telmisartan and the positively charged ciprofloxacin species, but they are quite 
large for labetalol and haloperidol below pH 3.5. In fact, log Do/w values obtained by the 
shake-flask in these acidic conditions were not included in the fittings of Eq. (4). Differences 
for ionized species might be attributed to diverse ion pairing effects between the buffering 
agent in the case of the shake-flask and the potassium chloride used for the potentiometric 
method. The lowest pKa of haloperidol corresponded to the weak tertiary amine, and had a 
value of 8.48. There was no apparent reason for the decrease in the shake-flask lipophilicity 
below pH 3.5, except for the presence of phosphoric acid and dihydrogen phosphate as 
buffering species (Table 2); above pH 3.75, acetic acid and acetate were used instead.. 
However, the particular reasons for this behavior remain unclear and require further 
investigation. For the ciprofloxacin there was a slight difference between the shake-flask and 
the potentiometric profiles in the acidic region corresponding to the cationic acid species. In 
fact, the 
'
a1pK  value fitted from shake-flask data (Table 4), which exhibited a relatively high 
fitting error, was about 2 units lower in relation to the pKa determined in the present work by 
the reference potentiometric method and the values found in the literature [19]. Thus, high 
'
a1pK  difference was likely due to the very low log Po/w values of both neutral and cationic 
species of ciprofloxacin and the small difference between them, which led to high fitting 
errors. Measured log Do/w values for this fluoroquinolone in the region buffered by acetic 
acid/acetate were slightly higher than expected, suggesting some kind of analyte–buffer 
interaction. 
 In summary, assuming that consistent lipophilicity values are obtained by both the 
shake-flask and the potentiometric methods, the latter seems to be more convenient because 
of the shorter determination times. In addition, potentiometry removes the need for the 
preparation of several pH buffers and avoids the effect of different buffer counter-ions on the 
lipophilicity of ionized acid-base compounds. 
Similarly to Eq. (4), a CHI profile can be defined as a function of the CHI of 
individual species, acid-base constants, and pH of the medium [20]: 
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where s is an empirical parameter accounting for the dynamics of the gradient elution [21]. 
The solvent change during the run implies continuous variations in the mobile phase pH and 
the analyte pKa. In most cases CHI values can be rapidly obtained for neutral and ionized 
species, the pH range of applicability only being limited by the stability of the 
chromatographic column. Since CHIMeCN measurements are based on a fast gradient using 
acetonitrile as the organic modifier, pKa values of Eq. (5) are an average of the pKa values in 
these hydro-organic solvent mixtures and do not match the potentiometric (or shake-flask) 
aqueous pKa (Table 4). This is why the CHI profiles did not match the log Do/w profiles, as 
shown in Fig. 2, although they showed a similar trend. In the case of mebendazole, which 
exhibited a difference between consecutive pKa values of 6.35 units, no significant changes 
were observed in CHI value (from 60 to 62) in the studied pH range. The CHI profile 
obtained for labetalol was consistent with that obtained in a previous study [20], showing that 
CHI values are indeed independent of the particular C18 column employed. 
Although general conversion between chromatographic and log Po/w lipophilicity 
scales is in principle possible [22, 23], it can only be applied to neutral compounds and 
requires the calculation of molecular descriptors (Eq. (3), Table 3). Even so, we applied Eq. 
(3) to convert the CHI to the log Do/w scale for all obtained CHI data for a particular 
compound. This conversion is illustrated in Fig. 2, i.e. the obtained CHI value of the drug can 
be read on the righthand y-axis and the corresponding calculated log Do/w (from Eq. 3 and the 
particular drug descriptor (Table 3)) on the lefthand y-axis. However as shown in Table 5, log 
Po/w values obtained from CHI measurements differed slightly from those measured by shake-
flask and potentiometry. The main reasons may lie in the nature of the CHI approach, since it 
is an indirect method for log Po/w determination, and in addition, for most of the zwitterionic 
compounds, there is the issue of the reduction of the molar fraction of neutral species when 
acetonitrile is added to the aqueous buffer to prepare the mobile phase. Thus, acidic groups 
increase their pKa values with the content of organic modifier, whereas basic groups show the 
opposite trend. For instance, benazepril has two functional groups with acid-base properties, a 
carboxylic aliphatic acid and secondary amine of aqueous pKa values of 3.35 and 5.43, 
respectively. Thus, in pure water, the neutral form of this compound is a zwitterion. When 
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30% of acetonitrile is added, the first pKa is expected to shift up to 3.95 and the second one to 
shift down to 4.96 [24], reducing the distance between pKa values from 2.1 to 1.0 units. When 
the percentage of  acetonitrile in the hydro-organic mixture exceeds 60%, the pKa variation 
continues until the amine becomes stronger (4.33) than the carboxylic acid (4.75), and thus 
the main neutral compound is no longer a zwitterion. The shorter the pKa distance, the lower 
the mole fraction of neutral species found in solution. Moreover, both the pKa and the pH of 
the mobile phase change with the organic modifier, which requires an accurate pH 
measurement of the mobile phase or alternatively some previous calculations in order to find 
the most appropriate pH for the aqueous buffer [24]. Therefore, even under the most favorable 
mobile phase pH, it is not possible to measure the retention of the isolated neutral species, but 
only a mixture of neutral and ionized forms.  
A second reason for the lower accuracy of chromatographic methods in relation to 
shake-flask and potentiometry arises from the molecular descriptors. They are always 
calculated from the uncharged form, even in the case of zwitterionic species, and this must 
affect the charge distribution and the geometry of the molecule, and consequently the 
accuracy of the molecular descriptors. 
 
4. Conclusions 
For the studied amphoteric compounds, the shake-flask and potentiometric methods led to 
very similar log Do/w pH-profiles, and consequently to comparable log Do/w profiles. 
Differences for ionized species between the two methods (e.g. haloperidol or labetalol at 
acidic pH) might be attributed to differential ion pairing effects between the buffering agent in 
the case of the shake-flask and the potassium chloride required for the potentiometric method. 
Since the phase equilibration method is extremely time consuming and requires buffers of 
different nature according to their buffer capacity and working pH, the potentiometric 
methods seems to be more advantageous. 
Prediction software can be very useful for defining the start-up conditions for the 
experimental determination, since they provide a preliminary estimate of log Do/w profiles 
over the whole pH range. However, their accuracy compared with experimental values may 
not be very good, and different prediction algorithms may lead to diverse results for the same 
compound. 
 The CHI methodology is very convenient for lipophilicity screening purposes, due to 
its rapidity and wide pH range of applicability, but the log Po/w values from CHI 
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measurements are expected to be less accurate than those obtained using the shake-flask and 
potentiometric methods. 
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TABLES 
 
Table 1. Studied compounds.  
Compound  Compound  
Benazepril 
 
Mebendazole 
 
Ciprofloxacin 
 
Nalidixic acid 
 
Esomeprazole 
 
Pantoprazole 
 
Haloperidol 
 
Sulfamethoxazole 
 
Labetalol 
 
Telmisartan 
 
 
  
2 
 
Table 2. Selected partition volumes of the shake-flask procedure.  
log Do/w range Vw/Vo (V in μL) 
log Do/w < -1 200/5000, 500/5000, 500/500 
-1 < log Do/w < 0 500/5000, 500/500 
0 < log Do/w < 1.5 500/5000, 500/500, 1000/100 
1.5 < log Do/w < 3.0 1000/10, 3000/10, 5000/10 
3.0 < log Do/w < 3.5 3000/10, 5000/10 
 
  
3 
 
Table 3. CODESSA molecular descriptors used in the log Po/w determination from 
chromatographic measurements. 
Compounds HDCA-1/TMSA HOMO-LUMO 
Benazepril 3.64·10
-3
 9.03 
Ciprofloxacin 8.69·10
-3
 8.26 
Esomeprazole 3.46·10
-3
 8.11 
Haloperidol 3.47·10
-3
 8.42 
Labetalol 9.33·10
-3
 9.17 
Mebendazole 8.64·10
-3
 8.35 
Nalidixic acid 8.70·10
-3
 8.47 
1-Naphthoic acid 7.24·10
-3
 8.16 
Pantoprazole 5.75·10
-3
 8.38 
Sulfamethoxazole 4.99·10
-3
 8.67 
Telmisartan 3.25·10
-3
 7.80 
 
  
4 
 
Table 4. Comparison between the potentiometric reference acidity constants and the fitted 
ones from shake-flask (Eq. 4) and CHI (Eq. 5) vs. pH profiles.  
  Potentiometric
b
  Shake-flask
c
  CHI 
Compound Class
a
 
''
ap jK   
'
ap jK   
'
ap jK  s 
Benazepril H2X
+
 3.35±0.25  2.73±0.18  - - 
HX± 5.43±0.02  5.87±0.11  4.86±0.08 1.12±0.16 
Ciprofloxacin H2X
+
 6.20±0.05  4.08±0.50  - - 
HX± 8.56±0.04  8.85±0.17  7.34±0.27 0.49±0.18 
Esomeprazole H2X
+
 4.60±0.08  5.37±0.20  3.46±0.96 0.84±0.71 
HX± 8.86±0.04  8.69±0.08  10.13±0.23 0.89±0.19 
Haloperidol H2X
+
 8.54±0.09  8.12±0.13  8.15±0.09 0.70±0.09 
HX 10.98±0.15  -  - - 
Labetalol H2X
+
 7.41±0.04  7.59±0.32  8.00±0.59 0.72±0.46 
 HX± 9.37±0.08  9.32±0.23  9.99±0.08 1.82±0.94 
Mebendazole H2X
+
 3.53±0.04  3.59±0.16  - - 
HX 9.88±0.06  9.43±0.17  - - 
Nalidixic acid HX 6.00±0.03  6.41±0.11  7.58±0.04 1.04±0.11 
Pantoprazole HX 8.22±0.09  8.38±0.06  9.23±0.05 1.03±0.13 
Sulfamethoxazole HX 5.65±0.03  5.83±0.04  6.47±0.09 0.64±0.06 
Telmisartan H3X
+
 3.01±0.09  3.28±0.28  - - 
H2X
±
 4.39±0.02  4.60±0.44  4.61±0.04 0.92±0.05 
HX- 6.02±0.03  5.61±0.35  - - 
a
The acidic form of the compound is shown; 
b
I=0.15M (KCl); 
c
I=0.10M (several buffers). 
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Table 5. Measured lipophilicity for the studied amphoteric and zwitterionic compounds.  
  Shake-flask Potenciometric CHI method 
Compound Class log Po/w (I=0.10M) log Po/w (I=0.15M) CHIMeCN log Po/w 
Benazepril H2X
+
 - 0.07±0.10 - - 
HX± 1.24±0.08 1.38±0.01 65.3±0.5 2.07 
X- - - 52.2±0.2 - 
Ciprofloxacin H2X
+
 -1.98±0.21 -1.59±0.12 - - 
HX± -1.13±0.09 -1.15±0.03 31.5±0.7 0.71 
X- - - 21.6±0.8 - 
Esomeprazole H2X
+
 - - 46.8±5.3  
HX± 2.23±0.05 2.17±0.01 53.6±0.3 1.50 
X- - 0.39±0.04 32.8±2.6 - 
Haloperidol H2X
+
 1.53±0.04 1.38±0.03 61.8±0.7 - 
HX 3.52±0.09 3.61±0.01 89.3±0.9 3.56 
Labetalol H2X
+
 0.17±0.08 0.18±0.03 45.6±0.4 - 
HX± 1.45±0.17 1.37±0.02 52.7±2.8 1.89 
X- - - 39.6±0.7 - 
Mebendazole H2X
+
 - 0.71±0.14 61.6±0.4 - 
HX 3.09±0.07 2.92±0.10 - 2.47 
Nalidixic acid HX 1.36±0.08 1.48±0.02 61.9±0.5 2.48 
X- -1.58±0.07 - 27.5±0.4 - 
Pantoprazole HX 2.07±0.04 1.84±0.01 57.2±0.2 1.91 
X- - -0.98±0.28 39.6±0.7 - 
Sulfamethoxazole HX 0.86±0.02 0.90±0.01 47.9±0.7 1.24 
X- - - 20.8±0.5 - 
Telmisartan H3X
+
 - 1.45±0.29 - - 
H2X
±
 4.18±0.29 3.54±0.11 90.3±2.4 2.44 
HX
-
 1.46±0.09 1.41±0.05 52.7±0.4 - 
 
1 
 
FIGURE CAPTIONS  
 
Figure 1. Maximum advisable mole fraction of neutral species for an amphoteric compound 
depending on the pKa distance between acidic and basic groups. 
 
Figure 2. Lipophilicity profiles of some ordinary and zwitterionic ampholytes of 
pharmaceutical interest measured by different methods: a) (●) shake-flask with 
chromatographic UV detection; b) (solid lines) potentiometry; c) (■) CHI; d) (dotted lines) 
estimated from ACD/Labs, Classic approach; e) (dashed lines) estimated from ACD/Labs, 
GALAS approach. For shake-flask and CHI, symbols represent experimental measurements 
and lines are the fittings to corresponding models (Eqs. (4) and (5)). The scale of the right 
CHI axis has been set to match that of the left log Po/w axis by means of Eq. (3) and the 
molecular descriptors presented in Table 3. 
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